Posts
Showing posts with label Alice Dreger. Show all posts
Showing posts with label Alice Dreger. Show all posts
Tuesday, 25 August 2015
Alice Dreger Resigns from Northwestern University Following Pathetic Censoring by Management
Today, I learned that Alice Dreger, professor of clinical medical humanities and bioethics at Northwestern University's Feinberg School of Medicine, internationally celebrated for her work on the practices and policies around intersex and ambiguous sex conditions, especially in small children, yesterday chose to hand in her letter of resignation, following a pathetically prude and spineless piece of ham-handed censorship of her and a colleagues' work by her own medical school dean, Eric Nielson last year, and subsequent lack of university provost, Daniel Linzer, to assure her that anything like that would never occur again.
Read it all in Alice's own words, including the letter of resignation itself, at her website and blog, here.
As Alice has just published and already won acclaim for the book, Galileo's Middle Finger, which centers around exactly the issue of censorship and supression of academic publication and scientific ideas, the development has a bizarre twist to it, indeed. Today, apparently, it is not the clerics or the many versions of politburos that academics and scientists have to fear will silence what they have to tell the world, but the leaders of the very institutions supposed to sternly guard against anything in that vein.
Tuesday, 11 August 2015
The Pinker Stinker And The One Bioethicist That Really Should Get Out of the Way
Back from summer holidays, I was greeted by what has seemingly been the big news in bioethics this and the last month: Steven Pinker's article in the Boston Globe, where he tells the field of bioethics and bioethicists to "get out of the way" and stop debating new technologies, such as the CRISP/Cas9 "genome editing", which I commented on earlier this year – seemingly because Steven Pinker himself has already done all of the bioethics needed doing on this and related subjects (apparently by saying that these technologies will become very good, albeit we don't know much about them yet). That is, he seems at first glance to be performing the very act he urges so strongly against: doing some (rogue elephant) bioethics in this sacred area and, in effect, revealing himself as a ghastly closet bioethicist – who, according to his own logic, should then get out of the way, I presume.
But this is not the end of the folly of Pinker's article, as he seems to be confusing a great number of things, such as bioethics (the academic field where various aspects of bioscience and biotechnology is debated and probed in ethical terms using intellectual tools of moral philosophy and social science), legal and semi-legal regulation of science and technology (adopted by governments, international bodies and professions to control how new ideas and gadgets are introduced and used), and the idea of a temporary moratorium on particular applications of new technologies while exploring them further in more controlled settings (like the 1974 Asilomar consensus on recombinant DNA technology) decided not by bioethicists, but by the concerned scientists themselves – albeit based (one presumes) on views on bioethical issues. Read my distinguished colleagues Richard Ashcroft, Alice Dreger and Julian Savulescu, who I admire for their extreme charity and patience, in turn pointing to several others, to unveil many more subtle incoherent twists apparently resting inside Pinker's stinker, and how these, at the end of the day, leaves him even worse off in terms of consistency than what the initial impression holds out.
On my own part, I can't free myself from the reflection that if there is one bioethicist who really should get out of the way, it is the one who thinks that the fact the he/she has formed an (no matter how badly argued) opinion on something is a reason for others not to voice and argue their own.
Thursday, 17 April 2014
Old AJOB Rut re. Prenatal Dex Picks up New Steam as Undisclosed Double Loyalties and Dependencies of Now Editor Skip Nelson are Suggested
Amended 2014-04-18: see bottom of this post!
I'm sure several readers remember a long series of posts across 2011-12, connected to a series of internal troubles in the management of the American Journal of Bioethics. One of the roots of all that mess was a controversy that eventually led to the resignation of Hilde Lindemann from the AJOB editorial board in protests of its managerial operations, followed by other weighty ones later by, e.g. Udo Schuklenk and John Lantos. Eventually, after much external pressure, following a less than elegantly handled stepping over to private business by then editor-in-chief, Glenn McGee (later to become CEO of the now defunct stem cell banking, cosmetics and therapeutic business RNL Europe), the drop-out of the AJOB operation of both him and his wife Summer Johnson McGee, who had initially been appointed to advance to co-editor with the new EiC appointed to succeed McGee.
The last post with any substance out of this mess was this one, and the entire series is found here.
The affair leading to the resignation of Lindemann connected to a critical scrutiny, and eventual letter to the FDA, signed by a large number of bioethicists, regarding some unresearched, non-evidence based, experimental off-label prenatal drug treatment at the Mount Sinai hospital with regard to congenital adrenal hyperplasia. This led to a long series of complicated controversies involving AJOB, later leading up to the developments summarised above, and one of those concerned the possible conflict of interests of several centrally placed AJOB managerial figures. Among those involved was Robert “Skip” Nelson, now editor-in-chief of the AJOB Empirical Bioethics journal, at the time ethicist linked to the FDA (he still is, as a matter of fact), who sent a letter to the Office for Human Research Protections on the Prenatal Dex case, as it came to be known, clearing the accused doctor of having broken any FDA regulations. Now it is reported that, apparently, Nelson at the same time had close and live ties, to AJOB and the people in the management who were deeply involved in one side of the controversy. That is, it is argued in a recent post by Alice Dreger and Ellen K Feder (who belong clearly to the other side, it must be added), one of the prime expert sources had hidden loyalties and dependencies that remained undisclosed and is now holding a gallant EiC title in the AJOB family of journals.
The whole story and argument is told much better than I ever could by Alice Dreger and Ellen K. Feder themselves at the superb Canadian Impact Ethics blog.
Amendment:
Skip Nelson contacted me personally after posting the first version of this report, and made clear that he finds nothing new in what is described by Dreger and Feder, that no payments to him from AJOB have ever been involved in his service as EiC, that he performs this job as part of his FDA assignment, and that what he claimed in his letter to the OHRP regarding Prenatal Dex remains true (Dreger's and Feder's view on that is set out here). Nelson also told me that he has no plan to respond publicly to Dreger and Feder. This post has been amended in the light of that in a few places above.
I'm sure several readers remember a long series of posts across 2011-12, connected to a series of internal troubles in the management of the American Journal of Bioethics. One of the roots of all that mess was a controversy that eventually led to the resignation of Hilde Lindemann from the AJOB editorial board in protests of its managerial operations, followed by other weighty ones later by, e.g. Udo Schuklenk and John Lantos. Eventually, after much external pressure, following a less than elegantly handled stepping over to private business by then editor-in-chief, Glenn McGee (later to become CEO of the now defunct stem cell banking, cosmetics and therapeutic business RNL Europe), the drop-out of the AJOB operation of both him and his wife Summer Johnson McGee, who had initially been appointed to advance to co-editor with the new EiC appointed to succeed McGee.
The last post with any substance out of this mess was this one, and the entire series is found here.
The affair leading to the resignation of Lindemann connected to a critical scrutiny, and eventual letter to the FDA, signed by a large number of bioethicists, regarding some unresearched, non-evidence based, experimental off-label prenatal drug treatment at the Mount Sinai hospital with regard to congenital adrenal hyperplasia. This led to a long series of complicated controversies involving AJOB, later leading up to the developments summarised above, and one of those concerned the possible conflict of interests of several centrally placed AJOB managerial figures. Among those involved was Robert “Skip” Nelson, now editor-in-chief of the AJOB Empirical Bioethics journal, at the time ethicist linked to the FDA (he still is, as a matter of fact), who sent a letter to the Office for Human Research Protections on the Prenatal Dex case, as it came to be known, clearing the accused doctor of having broken any FDA regulations. Now it is reported that, apparently, Nelson at the same time had close and live ties, to AJOB and the people in the management who were deeply involved in one side of the controversy. That is, it is argued in a recent post by Alice Dreger and Ellen K Feder (who belong clearly to the other side, it must be added), one of the prime expert sources had hidden loyalties and dependencies that remained undisclosed and is now holding a gallant EiC title in the AJOB family of journals.
The whole story and argument is told much better than I ever could by Alice Dreger and Ellen K. Feder themselves at the superb Canadian Impact Ethics blog.
Amendment:
Skip Nelson contacted me personally after posting the first version of this report, and made clear that he finds nothing new in what is described by Dreger and Feder, that no payments to him from AJOB have ever been involved in his service as EiC, that he performs this job as part of his FDA assignment, and that what he claimed in his letter to the OHRP regarding Prenatal Dex remains true (Dreger's and Feder's view on that is set out here). Nelson also told me that he has no plan to respond publicly to Dreger and Feder. This post has been amended in the light of that in a few places above.
Sunday, 16 September 2012
Further on what's Cookin' at AJOB and Bioethics.net
I have now received conformation and independent corroboration of the rumours and signs I reported about before, which due to a number of factors I was unsure how to assess. Summer Johnson McGee has indeed stepped out of the management of the American Journal of Bioethics, and also announced that she are cutting her ties to Bioethics.net. The actual letter, or email, of resignation has now been forwarded to me and is here shown in its entirety:
From: Summer <summer.mcgee@me.com>
Subject: Leaving AJOB
Date: 10 September 2012 2:31:21 PM CDT
Cc: "pwolpe@emory.edu Wolpe" <pwolpe@emory.edu>, "Robert \"Skip\" Nelson" <robert.nelson@fda.hhs.gov>, David Magnus <dmagnus@stanford.edu>
Friends of The American Journal of Bioethics and bioethics.net,I want to share with all of you that Friday, September 14, 2012 will be my last day at The American Journal of Bioethics and bioethics.net. In mid-August, I had detailed conversations with both David Magnus and the publisher about my desire to leave AJOB. I have elected also that bioethics.net, the blog, the weekly newsletter, and all of its social networking sites (Facebook, Twitter, LinkedIn) will no longer be owned and operated by me nor will the editorial office reside with me any longer. I have so enjoyed working with you as peers, and I owe you a succinct explanation for my departure. I firmly believe that we are right to be proud of the Journal's last twelve years, the first era of The American Journal of Bioethics. AJOB accomplished things that no one in bioethics or publishing thought possible, least of all its editors and staff. Until a few months ago, I often said that the work I did for AJOB felt impactful and rewarding, even important. AJOB no longer feels that way to me. Whether it is me, the field, or the journal that has changed, I know that I no longer want to lead our field's most cited journal.So, with thanks to those who have asked me not to depart, I feel I must leave the Journal, a decision made much easier because I know it is in the competent hands of David Magnus and the editorial staff he and I hired in the last few months. It has been a privilege to spend the last four years working with the journal’s editorial board, authors, peer reviewers, and readers. My departure from our journal is of course very emotional for me. AJOB has been my labor of love for a very long time. I thank each of you who contributed to that experience for me personally and professionally; your faith in the journal and in me has been unwavering and unforgettable.I wish The American Journal of Bioethics, its current editors, editorial board, and readers the best of luck in its next era. I bid you a fond, bittersweet, farewell.Cordially,Summer Johnson McGee, PhD
The bulk of the text is what is (or was) actually quoted in William Heisel's mysteriously shut down post at Reporting on health (of which you can read a web cached version here), which makes that shut down even more strange.
In any case, the text does not really throw any light on the specifics that has led to Summer's decision. Heisel, as I mentioned in my former post, has a vaguely hinted guess. And in a blog post at Psychology Today, bioethics researcher Alice Dreger offers further possible reasons for Johnson McGee to abandon ship. These, as it were, are further alleged conflict of interest cases that may have been severely manhandled by the old AJOB management, but which are not explicitly connected to the scandal around possibly pharma corrupted pain medication research, that I told about in the former posting, and more extensively in another one before. That is, there may be yet another complex of COI problems at AJOB to which Johnson McGee (and her husband and former editor in chief, Glenn McGee) might have been connected. In this case, the connection is to clinical experiments involving drugs and prenatal diagnosis on fetuses and children with hereditary abnormalities in the sex-hormone production, which Dreger and colleagues critically assess in a very recent article. In fact, this potential problem for AJOB is connected also to members of its editorial and conflict of interest boards, as well as the editor in chief of its sibling journal AJOB Primary Research, Robert Nelson.
In any case, Dreger in her post describes in exact terms what that is about, and reports that she and a colleague have just written the new AJOB management to look at the matter with fresh eyes in light of what has recently come to pass. The ball is now in the hands of suddenly sole editor in chief, David Magnus.
As for my own worries around the integrity of AJOB, having to do with the not very sound financial ties between the former editor in chief and Bioethics.net, things are still unclear. Nothing in Johnson McGee's letter makes any more clear how the relationship between the new AJOB management, AJOB itself and Bioethics.net now looks like. Do any of the editors of AJOB have financial interests in Bioethics.net that, together with the role of Bioethics.net in the AJOB operation, provide incentives for making editorial decisions based on other grounds that those that should guide a scientific editor? This remains to be seen.
In any case, the text does not really throw any light on the specifics that has led to Summer's decision. Heisel, as I mentioned in my former post, has a vaguely hinted guess. And in a blog post at Psychology Today, bioethics researcher Alice Dreger offers further possible reasons for Johnson McGee to abandon ship. These, as it were, are further alleged conflict of interest cases that may have been severely manhandled by the old AJOB management, but which are not explicitly connected to the scandal around possibly pharma corrupted pain medication research, that I told about in the former posting, and more extensively in another one before. That is, there may be yet another complex of COI problems at AJOB to which Johnson McGee (and her husband and former editor in chief, Glenn McGee) might have been connected. In this case, the connection is to clinical experiments involving drugs and prenatal diagnosis on fetuses and children with hereditary abnormalities in the sex-hormone production, which Dreger and colleagues critically assess in a very recent article. In fact, this potential problem for AJOB is connected also to members of its editorial and conflict of interest boards, as well as the editor in chief of its sibling journal AJOB Primary Research, Robert Nelson.
In any case, Dreger in her post describes in exact terms what that is about, and reports that she and a colleague have just written the new AJOB management to look at the matter with fresh eyes in light of what has recently come to pass. The ball is now in the hands of suddenly sole editor in chief, David Magnus.
As for my own worries around the integrity of AJOB, having to do with the not very sound financial ties between the former editor in chief and Bioethics.net, things are still unclear. Nothing in Johnson McGee's letter makes any more clear how the relationship between the new AJOB management, AJOB itself and Bioethics.net now looks like. Do any of the editors of AJOB have financial interests in Bioethics.net that, together with the role of Bioethics.net in the AJOB operation, provide incentives for making editorial decisions based on other grounds that those that should guide a scientific editor? This remains to be seen.
Subscribe to:
Posts (Atom)